Phase 2 Study of PTI-428 + Symdeko Planned to Initiate in 3Q'18; Study Intended to Expand Population of CF subjects in Phase 3 to Include Both Orkambi and Symdeko Standard of Care
PR Newswire
CAMBRIDGE, Mass., April 17, 2018
PR Newswire
CAMBRIDGE, Mass., April 17, 2018
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey